We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Analysis of breast cancer mortality in the US-1975 to 2019.
- Authors
J. L., Caswell-Jin
- Abstract
This modelling study used aggregated observational and clinical trial data on dissemination and effects of screening and treatment to develop four Cancer Intervention and Surveillance Modeling Network (CISNET) models simulating US breast cancer mortality rates to determine the association between metastatic breast cancer treatment and breast cancer mortality. US age-adjusted breast cancer mortality rate was 48 per 100,000 women in 1975 and 27 per 100,000 women in 2019. A combination of screening, stage I-III treatment, and metastatic treatment was associated with a 58% reduction (range 55-61%) in breast cancer mortality, with 29% (range 19-33%) associated with treatment of metastatic breast cancer, 47% (range 35-60%) associated with stage I-III breast cancer treatment, and 25% (range 21-33%) with screening. The greatest change in survival after metastatic recurrence occurred between 2000 and 2019, from 1.9 years (range 1.0-2.7 years) to 3.2 years (range 2.0-4.9 years). While the median survival for ER-negative/ERBB2-negative breast cancer improved by only 0.5 years (range 0.3-0.8 years), median survival for ER-positive/ERBB2-positive breast cancer improved by 2.5 years (range 2.0-3.4 years).
- Subjects
UNITED States; BREAST tumor treatment; EARLY detection of cancer; METASTASIS; TUMOR classification; BREAST tumors
- Publication
Breast Cancer Research Review, 2024, Issue 42, p5
- ISSN
1179-4976
- Publication type
Article